Microdacyn for wound cleansing
Severe leg ulcers, pressure ulcers and diabetic foot cause great suffering for the affected and is associated with a large cost for the healthcare system. These wounds are difficult to treat and there is no consensus on best treatment. Microdacyn, formerly Dermacyn, is marketed as "an effective agent for the care and healing of chronic wounds, diabetic foot, burns, eye infection, viruses and fungi." and is approved as a Class IIB medical device product.
Low arousal approach for young people with externalized behaviour problems
Auricular acupuncture in prescription drug dependence detoxification
Auricular acupuncture in insomnia treatment
Impact on coagulation due to coronavirus
Family group conference
Interventions to motivate a healthier lifestyle in psychiatry outpatients
Clinical Frailty Scale in prediction of mortality, disability and quality of life for patients in need of intensive care
Non-invasive respiration in patients with covid-19 respiratory failure during hospitalization
SBU and COVID-19
SBU closely monitors what actions other countries are taking to meet the needs of decision- and policymakers to respond to the COVID-19 pandemic. Via the International organisation of HTA, INAHTA, SBU shares and exchanges information to support staff and decision-makers in health care and social services.
SBU is also in contact with the other Swedish agencies within the national health care sector who currently are working intensively to support both the health care services as well as care homes.
